Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

References

• Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997;102:35S–9
   Google Scholar
• The burden of musculoskeletal conditions at the start of the new millennium: a report of a WHO scientific group. WHO Technical Report Series 919, World Health Organization, Geneva 2003. Health Technol Assess 2004;8: 1–78
   Google Scholar
• Melton LJ, 3rd. Hip fractures: a worldwide problem today and tomorrow. Bone, 1993;14(Suppl 1):S1–8
   PubMed Web of Science ®Google Scholar
• Klift M van der, Laet CEDH de, McCloskey EV, et al. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2002;17:1051–6
   PubMed Web of Science ®Google Scholar
• Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992;13(Suppl 1):S7–15
   PubMedGoogle Scholar
• Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998;8:611–7
   PubMed Web of Science ®Google Scholar
• SIGN (2003) Management of osteoporosis. Scottish Intercollegiate Guidelines Network. Available from http://www.sign.ac.uk [Last accessed 6 June 2007]
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118–24
   PubMed Web of Science ®Google Scholar
• Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med 2005;26:203–19
   Google Scholar
• Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999–2006
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Conzelmann M, Stahelin HB, et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? Osteoporos Int 2006;17:656–63
   Google Scholar
• Staud R. Vitamin D: more than just affecting calcium and bone. Curr Rheumatol Rep 2005;7:356–64
   PubMedGoogle Scholar
• Blake AJ, Morgan K, Bendall MJ, et al. Falls by elderly people at home: prevalence and associated factors. Age Ageing 1988;17:365–72
   PubMed Web of Science ®Google Scholar
• Cummings SR, Nevitt MC. Falls. N Engl J Med 1994;331:872–3
   PubMed Web of Science ®Google Scholar
• Drinka PJ. The importance of parathyroid hormone and vitamin D status in the treatment of osteoporosis and renal insufficiency. J Am Med Dir Assoc 2006;7:S5–9
   PubMedGoogle Scholar
• Forli L, Halse J, Haug E, et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med 2004;256:56–62
   PubMed Web of Science ®Google Scholar
• Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004;80:1706S–9
   Google Scholar
• Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4–8
   PubMed Web of Science ®Google Scholar
• Pasco JA, Henry MJ, Kotowicz MA, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res 2004;19:752–8
   PubMed Web of Science ®Google Scholar
• Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 1996;155:1113–33
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
   Google Scholar
• Malavolta N, Pratelli L, Frigato M, et al. The relationship of vitamin D status to bone mineral density in an Italian population of postmenopausal women. Osteoporos Int 2005;16:1691–7
   PubMed Web of Science ®Google Scholar
• von Mühlen DG, Greendale GA, Garland CF, et al. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int 2005;16:1721–6
   Google Scholar
• Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996;51:145–7
   Google Scholar
• Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1–160
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6:1–146
   PubMedGoogle Scholar
• Slobbe LCJ, Kommer GJ, Smit JM Kosten van ziekten in Nederland 2003. Zorg voor euro’s [Costs of illness in the Netherlands 2003] Rijksinstituut voor Volksgezondheid en Milieu, RIVM; 2006
   Google Scholar
• Osteoporose Tweede herziene richtlijn 2002. English summary published in Pols HA, Wittenberg J. CBO guideline “Osteoporosis” (second version). NTVG Ned Tijdschr Geneeskd 2002;146:1359–63.
   Google Scholar
• Centraal Bureau voor de Statistiek [Central Office for Statistics]. Statline database, 2004. Available from http://www.cbs.nl [Last accessed 27 July 2007]
   Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15 721–39
   PubMed Web of Science ®Google Scholar
• Government Actuary Department, 1999. Available from http://www.gad.gov.uk [Last accessed 14 July 2005]
   Google Scholar
• Oden A, Dawson A, Dere W, et al. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998;8:599–603
   PubMed Web of Science ®Google Scholar
• Meyer HE, Tverdal A, Falch JA, Pedersen JI. Factors associated with mortality after hip fracture. Osteoporos Int 2000;11 228–32
   PubMed Web of Science ®Google Scholar
• Poor G, Atkinson EJ, O’Fallon WM, Melton III. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res 1995;319:260–5
   PubMed Web of Science ®Google Scholar
• Todd CJ, Freeman C, Camilleri-Ferrante C, Laxton C, Muriel P, Palmer C et al. Anglian audit of hip fracture 2. Cambridge: Cambridge Health Services Research Group, University of Cambridge; 1999.
   Google Scholar
• Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey [comment]. BMJ 1998;316 736–41
   PubMed Web of Science ®Google Scholar
• British National Formulary. Available from http://www.bnf.org/bnf/bnf/current/openat/index.htm [Last accessed 30 June 2005]
   Google Scholar
• CvZ. (College voor Zorgverzekering) [Health Care Insurance Board]. Z-index. Available from http://www.medicijnkosten.nl [Last accessed 30 June 2005]
   Google Scholar
• Curtis L, Netten A (Personal Social Services Research Unit). Unit costs of health and social care 2004. Available from http://www.pssru.ac.uk [14 July 2005]
   Google Scholar
• Oostenbrink JB, Koopmanschap MA, Rutten FF. Manual for cost calculations: methods and recommended prices for economic evaluations in health care. Handleiding voor kostenberekeningen: methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor zorgverzekeringen, 2004
   Google Scholar
• Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002;13:765–7
   PubMed Web of Science ®Google Scholar
• Stevenson MD, Oakley J, Chilcott JB. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 2004;24:89–100
   Google Scholar
• Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004;8:iii,1–78
   Google Scholar
• Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215–24
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22
   PubMed Web of Science ®Google Scholar
• Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2007 [Epub ahead of print 13 Nov 2007]
   Google Scholar
• Adachi J, Lynch N, Middelhoven H, et al. The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 2007;8:97 [Epub ahead of print 26 Sept 2007]
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686–94
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023–31
   PubMed Web of Science ®Google Scholar
• Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383–91
   Google Scholar